Conditioning plan for kids with AML before stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or younger when AML was first diagnosed (and 21 or younger at transplant).
- You must have acute myeloid leukemia (AML) and your doctors must recommend a stem cell transplant with donated cells (not your own cells).
- The transplant must be done at a hospital that is participating in this study.
- You must not have certain other diseases (like MDS or JMML) instead of AML.
- You must be healthy enough for chemotherapy (a poor activity score and major organ problems can disqualify you).
- You must agree to the study and (if you can become pregnant) use reliable birth control and have a negative pregnancy test before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a stronger chemotherapy regimen before a stem cell transplant to see if it can reduce the chance of leukemia coming back. It is for adults with acute myeloid leukemia who are in first remission.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a modified conditioning regimen (a drug treatment given before a stem cell transplant) for people with chronic myeloid leukemia that has entered blast phase, an aggressive stage of the disease. The goal is to help prepare the body for a transplant and improve outcomes.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Hear when a new Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.